Chapter Overview
This chapter addresses concepts used as a foundation for bowel management in patients with cancer. Because cancer treatment can be very noxious and disrupt bowel function, a preventive approach is an important part of bowel management for patients with cancer. The 6 steps to good bowel management are assessment and diagnosis of bowel dysfunction, normalization of the bowel, establishment of expectations for bowel-movement frequency, development of a bowel management program, assessment of outcomes, and adjustment of the bowel management program through problem-solving. New and innovative approaches to management of bowel dysfunction covered in this chapter are (1) differentiation between low and high impactions in the treatment of impactions; (2) administration of milk-and-molasses enemas; (3) use of a bowel training program for patients with constipation or diarrhea or frequent stooling; and (4) use of a proven, nontraditional fiber regimen for patients with frequent stooling after colorectal surgery. Opiate-induced constipation may be effectively prevented using senna and docusate sodium. Gastrointestinal gas may be decreased through controlling the intake of certain foods. Diarrhea in patients with cancer may have various noncancer causes, including impaction, lactose intolerance, food allergies, and medication. The cause of diarrhea, not the symptom, must be treated for optimal relief.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Suggested Readings
Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 2000;5:250–259.
Baughan CA, Lanney PA, Buchanan RB, et al. Arandomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. Clinical Oncology 1993;5:19–24.
Bisanz A. Managing bowel elimination problems in patients with cancer. Oncology Nursing Forum 1997;24:679–686.
Brocklehurst JC. How to define and treat constipation. Geriatrics 1977;32:85–87.
Bruera E, Suarez-Almazor M, Velasco A, et al. The assessment of constipation in terminal cancer patients admitted to a palliative care unit: retrospective review. J Pain Symptom Manage 1994;9:515–519.
Cascinu S. Management of diarrhea induced by tumors or cancer therapy. Curr Opin Oncol 1995;7:325–329.
Cascinu S, Fedeli A, Fedeli S, et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993;11:148–151.
Chew SB, Tindal DS. Colonic J-pouch as a neorectum: functional assessment. Aust N Z J Surg 1997;67:607–610.
Cimprich B. Symptom management of constipation. Cancer Nurs Suppl 1985;8:39–42.
Cox GJ, Matsui SM, Lo RS, et al. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 1994;107:1398–1407.
Daniele B, Perrone F, Gallo C, et al. Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut 2001;48:28–33.
Glare P, Lickiss JN. Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J Pain Symptom Manage 1992;7:369–371.
Goldstein F, Khoury J, Thornton JJ. Treatment of chronic radiation enteritis and colitis with salicylazosulphapyridine and systemic corticosteroids. A pilot study. Am J Gastroenterol 1976;65:201–205.
Govindarajan R, Heaton KM, Broadwater R, et al. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 2000;356:566–567.
Hensinkveld RS, Mannis MR, Arsistabal SA. Control of radiation induced diarrhea with cholestyramine. Int J Radiat Oncol Biol Phys 1978;4:687–691.
Herbst F, Kamm MA, Nicholls RJ. Effects of loperamide on ileoanal pouch function. Br J Surg 1988;85:1428–1432.
Hoff P, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282–2292.
Ippoliti C. Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. Am J Health Syst Pharm 1998;55:1573–1580.
Iseminegr J, Hardy P. Bran works! Geriatric Nursing 1982;3(6):402–404.
Lamb L. Gaseous distention. In: Lawrence E, Lamb P, eds. The Health Letter (ISSN 0739-4217). Special Report 95. Irvine, CA: North America Syndicate, Inc. 1988.
Lembo A, Camilleri M. Chronic constipation. New Engl J Med 2003;349:1360–1368.
Levy MH. Constipation and diarrhea in cancer patients. Cancer Bulletin 1991;43:412–422.
Locke GR III, Pemberton JH, Phillips SF. American Gastroenterological Association medical position statement: guidelines on constipation. Gastroenterology 2000;119:1761–1778.
Longo WE, Vernava AM III. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum 1993;36:696–708.
Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer 1998;6:356–364.
O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770–776.
Portenoy RK. Constipation in the cancer patient: causes and management. Med Clin North Am 1987;71:303–311.
Pro B, Lozano R, Ajani J. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. Invest New Drugs 2001;19:341–343.
Rao S. Constipation: evaluation and treatment. Gastroenterol Clin North Am 2003;32:659–683.
Robinson CB, Fritch M, Hullett L, et al. Development of a protocol to prevent opioid-induced constipation in patients with cancer: a research utilization project. Clin J Oncol Nurs 2000;4:79–84.
Rutledge D, Engelking C. Cancer-related diarrhea: selected findings of a national survey of oncology nurse experiences. Oncol Nurse Forum 1998;25:861–872.
Savarese D, Al-zoubi A, Boucher J. Glutamine for irinotecan diarrhea. J Clin Oncol 2000;18:450–451.
Schang JC, Devroede G. Beneficial effects of naloxone in a patient with intestinal pseudoobstruction. Am J Gastroenterol 1985;80:407–411.
Society of Gastroenterology Nurses and Associates Core Curriculum Committee. Large intestine. In: Van Schaik T, ed. Gastroenterology Nursing a Core Curriculum. 1st ed. St. Louis, Mo: Mosby Year Book; 1993:146–158.
Wyman JB, Heaton KW, Wicks ACB. The effect on intestinal transit and the feces of raw and cooked bran in different doses. Am J Clin Nutr 1976;29:1474–1479.
Yeo CJ, Barry MK, Sauter P, et al. Erythromycin accelerates gastric emptying after pancreaticoduodenectomy. Ann Surg 1993;218:229–238.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Bisanz, A.K. (2005). Bowel Management in Patients with Cancer. In: Ajani, J.A., Lynch, P.M., Janjan, N.A., Curley, S.A. (eds) Gastrointestinal Cancer. M. D. Anderson Cancer Care Series. Springer, New York, NY. https://doi.org/10.1007/0-387-27285-2_19
Download citation
DOI: https://doi.org/10.1007/0-387-27285-2_19
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-22090-1
Online ISBN: 978-0-387-27285-6
eBook Packages: MedicineMedicine (R0)